On June 1, 2021 Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, reported the virtual symposium, "VISTA: A New Immune Checkpoint in Cancer, Autoimmunity and Beyond," taking place on June 18, 2021, 9:00-1:15 PM ET (Press release, Curis, JUN 1, 2021, View Source,-Inc-Announces-2021-Virtual-Symposium-VISTA-A-New-Immune-Checkpoint-in-Cancer,-Autoimmunity-and-Beyond [SID1234583314]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Leaders in immunology across industry and academia will gather to discuss emerging checkpoint molecule, VISTA, including its function, the role it plays in several disease areas and current development programs. The event is organized by Curis and will be hosted by Randolph Noelle, Ph.D., Professor of Microbiology and Immunology, Department of Microbiology and Immunology, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth; and Padmanee Sharma, M.D., Ph.D., Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, University of Texas, MD Anderson Cancer Center.
"Over the last several years, there have been significant advancements from both academia and industry in the understanding and pursuit of VISTA as a target for immunotherapy, including the advancement of our own anti-VISTA antibody, CI-8993, into clinical trials," said James Dentzer, President and Chief Executive Officer of Curis. "This symposium will bring together leading minds on the forefront of VISTA research and development to discuss the latest insights into this emerging checkpoint target and its potential applications in immuno-oncology, autoimmune diseases and other therapeutic areas."
Free to attend, the event features agenda topics including:
Overview of checkpoint therapy
Introduction of VISTA
VISTA regulation of the tumor microenvironment in human cancer
Discovery of anti-VISTA antibodies
VISTA counterreceptors
Industry Panel: VISTA advances into clinical development
To learn more about the symposium and register to attend please visit, https://bit.ly/3hBzIUj.